Skip to content
Biodatica
Start free

Dewpoint Therapeutics, Inc.

Boston, MA · also filed as None

OncologyFormed
Compare Sign in to watch

What changed

Study registered, no phase assigned: A Pilot Study of the VosCryoTM Breathalyser in Lung Cancer

4d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

67no change

Momentum 67 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

~120months

The last disclosed raise still models out past a year.

Stage

Formed

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Sep 1, 2026

    Advanced Lung Cancer · NOT_YET_RECRUITING · sponsor: Sheffield Teaching Hospitals NHS Foundation Trust · A Pilot Study of the VosCryoTM Breathalyser in Lung Cancer

    ClinicalTrials.gov · NCT07689968 (opens the source filing in a new tab)

  2. Filing

    Form D · $59M

    Sep 23, 2025

    Dewpoint Therapeutics, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0001828893-25-000002 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources